Literature DB >> 18184783

The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.

Benjamin B Land1, Michael R Bruchas, Julia C Lemos, Mei Xu, Erica J Melief, Charles Chavkin.   

Abstract

Stress is a complex human experience having both positive and negative motivational properties. When chronic and uncontrollable, the adverse effects of stress on human health are considerable and yet poorly understood. Here, we report that the dysphoric properties of chronic stress are encoded by the endogenous opioid peptide dynorphin acting on specific stress-related neuronal circuits. Using different forms of stress presumed to evoke dysphoria in mice, we found that repeated forced swim and inescapable footshock both produced aversive behaviors that were blocked by a kappa-opioid receptor (KOR) antagonist and absent in mice lacking dynorphin. Injection of corticotropin-releasing factor (CRF) or urocortin III, key mediators of the stress response, produced place aversion that was also blocked by dynorphin gene deletion or KOR antagonism. CRF-induced place aversion was blocked by the CRF2 receptor antagonist antisauvigine-30, but not by the CRF1 receptor antagonist antalarmin. In contrast, place aversion induced by the KOR agonist U50,488 was not blocked by antisauvigine-30. These results suggest that the aversive effects of stress were mediated by CRF2 receptor stimulation of dynorphin release and subsequent KOR activation. Using a phospho-selective antibody directed against the activated KOR to image sites of dynorphin action in the brain, we found that stress and CRF each caused dynorphin-dependent KOR activation in the basolateral amygdala, nucleus accumbens, dorsal raphe, and hippocampus. The convergence of stress-induced aversive inputs on the dynorphin system was unexpected, implicates dynorphin as a key mediator of dysphoria, and emphasizes kappa-receptor antagonists as promising therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184783      PMCID: PMC2612708          DOI: 10.1523/JNEUROSCI.4458-07.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

Review 1.  Drug addiction: the neurobiology of behaviour gone awry.

Authors:  Nora D Volkow; Ting-Kai Li
Journal:  Nat Rev Neurosci       Date:  2004-12       Impact factor: 34.870

2.  4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders.

Authors:  Guy Griebel; Jacques Simiand; Régis Steinberg; Mireille Jung; Danielle Gully; Pierre Roger; Michel Geslin; Bernard Scatton; Jean-Pierre Maffrand; Philippe Soubrié
Journal:  J Pharmacol Exp Ther       Date:  2002-04       Impact factor: 4.030

3.  Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus.

Authors:  J J Wagner; G W Terman; C Chavkin
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

4.  Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats.

Authors:  Y Shaham; D Funk; S Erb; T J Brown; C D Walker; J Stewart
Journal:  J Neurosci       Date:  1997-04-01       Impact factor: 6.167

5.  Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens.

Authors:  A M Pliakas; R R Carlson; R L Neve; C Konradi; E J Nestler; W A Carlezon
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

Review 6.  Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states.

Authors:  P W Gold; G P Chrousos
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

7.  Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.

Authors:  A W Zobel; T Nickel; H E Künzel; N Ackl; A Sonntag; M Ising; F Holsboer
Journal:  J Psychiatr Res       Date:  2000 May-Jun       Impact factor: 4.791

8.  The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats.

Authors:  S Erb; Y Shaham; J Stewart
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

9.  Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs.

Authors:  K E Gabry; G P Chrousos; K C Rice; R M Mostafa; E Sternberg; A B Negrao; E L Webster; S M McCann; P W Gold
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

10.  CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats.

Authors:  Y Shaham; S Erb; S Leung; Y Buczek; J Stewart
Journal:  Psychopharmacology (Berl)       Date:  1998-05       Impact factor: 4.530

View more
  303 in total

1.  Long-term effects of neonatal stress on adult conditioned place preference (CPP) and hippocampal neurogenesis.

Authors:  Sarah L Hays; Ronald J McPherson; Sandra E Juul; Gerard Wallace; Abigail G Schindler; Charles Chavkin; Christine A Gleason
Journal:  Behav Brain Res       Date:  2011-10-28       Impact factor: 3.332

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

3.  6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.

Authors:  Marie-Laure Rives; Mary Rossillo; Lee-Yuan Liu-Chen; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

4.  Effects of prolonged ethanol vapor exposure on forced swim behavior, and neuropeptide Y and corticotropin-releasing factor levels in rat brains.

Authors:  Brendan M Walker; David A Drimmer; Jennifer L Walker; Tianmin Liu; Aleksander A Mathé; Cindy L Ehlers
Journal:  Alcohol       Date:  2010-08-12       Impact factor: 2.405

5.  Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats.

Authors:  Patrick M Beardsley; Gerald T Pollard; James L Howard; F Ivy Carroll
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

6.  Medial dorsal hypothalamus mediates the inhibition of reward seeking after extinction.

Authors:  Nathan J Marchant; Teri M Furlong; Gavan P McNally
Journal:  J Neurosci       Date:  2010-10-20       Impact factor: 6.167

7.  Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.

Authors:  Stephanie L Grella; Douglas Funk; Kathy Coen; Zhaoxia Li; A D Lê
Journal:  Behav Brain Res       Date:  2014-02-28       Impact factor: 3.332

Review 8.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 9.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

10.  Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.

Authors:  Jessica P Anand; Vanessa R Porter-Barrus; Helen V Waldschmidt; Larisa Yeomans; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.